| Table of Contents |  |
|
Review Article
| ||||||
| Infusion reactions associated with use of biologic medicines in cancer therapy | ||||||
| Anubha Singh1, Deepak Kumar Singh2, Usha Bhoria3 | ||||||
|
1Senior Resident, Department of Laboratory Services, Employees' State Insurance Corporation Model Hospital, Ministry of Labor, Noida, Uttar Pradesh, India.
2Junior Specialist, Department of Laboratory Services, Employees' State Insurance Corporation Model Hospital, Ministry of Labor, Noida, Uttar Pradesh, India. 3Senior Specialist, Department of Laboratory Services, Employees' State Insurance Corporation Model Hospital, Ministry of labor, Noida, Uttar Pradesh, India. | ||||||
| ||||||
|
[HTML Full Text]
[PDF Full Text]
[Print This Article]
[Similar article in Pumed] [Similar article in Google Scholar] |
| How to cite this article |
| Singh A, Singh DK, Bhoria U. Infusion reactions associated with biologic medicines as cancer therapy. Oncocytology 2014;4:23–31. |
|
Abstract
|
|
Biologic medicines, such as monoclonal antibodies are gaining popularity for prevention and treatment of diseases. Due to their binding specificity for the molecular target of interest, or other biochemical pathways in human system, they provide benefits of lowering the unwanted systemic effects with an increase in efficacy. Studies on expression of molecular targets bestows one disadvantage of targeted therapies as molecular target of interest expresses in many instances on the normal cells as well, thereby disrupting normal cellular function and causing varying grades of toxicity. Though severe reactions are not common, mild-to-moderate infusion reactions has been associated with treatment with monoclonal antibodies. For achieving the treatment goal and future decisions, the proper assessment and evaluation of severity and nature of infusion reactions is required. Inappropriate assessment of adverse infusion reactions can affect the treatment decisions and prove to be life threatening. This review discusses the selected monoclonal antibodies which are used for treatment of life threatening conditions such as cancer. We have discussed the infusion reactions associated with both the monoclonal antibodies as well as monoclonal antibody-drug conjugates used for treatment of cancer.
| |
|
Keywords:
Infusion reactions, Biotherapeutics, Monoclonal antibody, Hypersensitivity
| |
|
[HTML Full Text]
[PDF Full Text]
|
|
Author Contributions
Anubha Singh – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Deepak Kumar Singh – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published Usha Bhoria – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published |
|
Guarantor of submission
The corresponding author is the guarantor of submission. |
|
Source of support
None |
|
Conflict of interest
Authors declare no conflict of interest. |
|
Copyright
© 2014 Anubha Singh et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information. |
|
|